Prognostic significance of programmed cell death ligand 1 (pd-l1), cd8+ tumor-infiltrating lymphocytes and p53 in non-small cell lung cancer: an immunohistochemical study | Zendy

Hayam E. Rashed | Zendy; Aziza E. Abdelrahman | Zendy; Mohamed Abdelgawad | Zendy; Safa A. Balata | Zendy; Mohamed El Shabrawy | Zendy

Open Access

Prognostic significance of programmed cell death ligand 1 (pd-l1), cd8+ tumor-infiltrating lymphocytes and p53 in non-small cell lung cancer: an immunohistochemical study

Author(s) -

Hayam E. Rashed,

Aziza E. Abdelrahman,

Mohamed Abdelgawad,

Safa A. Balata,

Mohamed El Shabrawy

Publication year - 2017

Publication title -

turkish journal of pathology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.305

H-Index - 14

eISSN - 1309-5730

pISSN - 1018-5615

DOI - 10.5146/tjpath.2017.01398

Subject(s) - cd8 , immunohistochemistry , tumor infiltrating lymphocytes , lung cancer , pd l1 , stromal cell , medicine , cancer research , immune system , cancer , immunotherapy , pathology , immunology

Programmed cell death ligand-1 interacts with the immune receptors on the surface of CD8+ tumor infiltrating lymphocytes and PD-1, thereby blocking its anti-tumor activity. Therapeutics suppression of this interaction will show a promise in the treatment of non-small cell lung cancer by restoring the functional anti-tumor T-cell activity. We aimed to evaluate the association between the immunohistochemical expression of PD-L1, stromal CD8+ tumor infiltrating lymphocytes and p53 with the clinicopathological characteristics, response to chemotherapy, progression-free-survival, and overall survival.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research